IRB-Approved Pilot Study Shows Efficacy in Reducing Withdrawal Symptoms
Springfield, MO – Oct. 29, 2019 – Shealy-Sorin Wellness announces the conclusion of a
12-month IRB-approved pilot study among a small prison population to test the use of the
Gamma PEMF Therapy device on patients with opioid addiction.
Participants were required to wear the Gamma PEMF Therapy device for at least one hour per
day for a period of 12 months. Participants maintained initial and weekly logs regarding their
symptoms. These weekly scores, on a 0-10 scale, were segmented into 3-month increments. All
subjects reported a marked decrease in common withdrawal symptoms, including opioid
cravings, night sweats, and nightmares.
The researchers demonstrated significant benefits for patients, including:
● Reduction in Opioid Craving Occurrence (98.2% reduction from baseline)
● Reduction in Nightmare Occurrence (65.4% reduction from baseline)
● Reduction in Night Sweat Occurrence (85% reduction from baseline)
Continued monitoring since completion of trial (February, 2019) shows all 10 subjects remain
free of opioids. Additionally, all subjects remain free from incarceration and have rejoined the
Gamma PEMF therapy is a safe and non-invasive treatment. Participants in the pilot program
will continue to be monitored for an additional year after completing the program. Though
further research is needed, this study demonstrates statistically-significant benefits for opioid
treatment with Gamma PEMF Therapy. Further studies are currently being undertaken using
Gamma PEMF Therapy to treat both Chronic Pain and Chronic Disease.
Shealy-Sorin Wellness Institute is a healthcare provider specializing in the treatment of chronic
pain, depression, and addiction. Dr. C. Norman Shealy is the President of Shealy-Sorin Wellness.
Long-time innovator and researcher Dr. Shealy pioneered the use of Electro-acupuncture, Spinal
Cord Stimulation, and Transcutaneous Electrical Nerve Stimulation.